Impact of burden on granulocyte clearance of bacteria in a mouse thigh infection model

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 10, 2010, Pages 4368-4372

  Drusano, G L ^a   Fregeau, Christine ^a   Liu, Weiguo ^a   Brown, D L ^a   Louie, Arnold ^a  

^a ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COUNT; BACTERICIDAL ACTIVITY; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; FEMALE; GRANULOCYTE; INFECTION; MICHAELIS MENTEN KINETICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; THIGH INFECTION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL LOAD; GRANULOCYTES; IMMUNOCOMPETENCE; MICE; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; THIGH;

EID: 77957338404     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00133-10     Document Type: Article

References (14)

1. Ambrose, P. G. 2008. Use of pharmacokinetics and pharmacodynamics in a failure analysis of community-acquired pneumonia: implications for future clinical trial study design. Clin. Infect. Dis. 47(Suppl. 3):S225-S231.
2. Andes, D., and W. A. Craig. 2002. Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models. Antimicrob. Agents Chemother. 46:1665-1670.
3. Carrol, E. D., M. Guiver, S. Nkhoma, L. A. Mankhambo, J. Marsh, P. Balmer, D. L. Banda, G. Jeffers, IPD Study Group, S. A. White, E. M. Molyneux, M. E. Molyneux, R. L. Smyth, and C. A. Hart. 2007. High pneumococcal DNA loads are associated with mortality in Malawian children with invasive pneumococcal disease. Pediatr. Infect. Dis. J. 26:416-422.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibiotic dosing of mice and men. Clin. Infect. Dis. 26:1-10.
5. Craig, W. A., and D. R. Andes. 2008. In vivo pharmacodynamics of ceftobiprole against multiple bacterial pathogens in murine thigh and lung infection models. Antimicrob. Agents Chemother. 52:3492-3496.
6. Eagle, H., R. Fleischman, and M. Levy. 1953. Continuous versus discontinuous therapy with penicillin: the effect of interval between injections on therapeutic efficacy. N. Engl. J. Med. 248:481-488.
7. Elliott, G. R., P. K. Peterson, H. A. Verbrugh, M. R. Freiberg, J. R. Hoidal, and P. G. Quie. 1982. Influence of subinhibitory concentrations of penicillin, cephalothin, and clindamycin on Staphylococcus aureus growth in human phagocytic cells. Antimicrob. Agents Chemother. 22:781-784.
8. Hope, W. W., G. L. Drusano, C. B. Moore, A. Sharp, A. Louie, T. J. Walsh, D. W. Denning, and P. A. Warn. 2007. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob. Agents Chemother. 51:285-295.
9. Leary, R., R. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. In Proceedings of the 14th IEEE Symposium on Computer-Based Medical Systems. IEEE Computer Society, Bethesda, MD. (Pubitemid 32806762)
10. Leijh, P., M. T. Van den Barselaar, T. L. van Zwet, I. Dubbeldeman-Rempt, and R. van Furth. 1979. Kinetics of phagocytosis of Staphylococcus aureus and Escherichia coli by human granulocytes. Immunology 37:453-465.
11. Louie, A., C. Fregeau, W. Liu, R. Kulawy, and G. L. Drusano. 2009. Pharmacodynamics of levofloxacin in a murine pneumonia model of Pseudomonas aeruginosa infection: determination of epithelial lining fluid (ELF) targets. Antimicrob. Agents Chemother. 53:3325-3330.
12. Louie, A., P. Kaw, W. Liu, N. Jumbe, M. H. Miller, and G. L. Drusano. 2001. Pharmacodynamics of daptomycin in a murine thigh model of Staphylococcus aureus infection. Antimicrob. Agents Chemother. 45:845-851.
13. Rodvold, K. A., D. P. Nicolau, T. P. Lodise, M. Khashab, G. Noel, J. B. Kahn, M. Gotfried, S. A. Murray, S. Nicholson, S. Laohavaleeson, P. R. Tessier, and G. L. Drusano. 2009. Identifying exposure targets for the treatment of staphylococcal pneumonia with eftobiprole. Antimicrob. Agents Chemother. 53:3294-3301.
14. Singer, M., S. Nambiar, T. Valappil, K. Higgins, and S. Gitterman. 2008. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia. Clin. Infect. Dis. 47(Suppl. 3):S216-S224.